Symbols / SMMT
SMMT Chart
About
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. The company was founded in 2003 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.67B |
| Enterprise Value | 11.81B | Income | -1.08B | Sales | — |
| Book/sh | 0.85 | Cash/sh | 0.92 | Dividend Yield | — |
| Payout | 0.00% | Employees | 265 | IPO | — |
| P/E | — | Forward P/E | -13.32 | PEG | — |
| P/S | — | P/B | 18.45 | P/C | — |
| EV/EBITDA | -10.79 | EV/Sales | — | Quick Ratio | 9.78 |
| Current Ratio | 9.87 | Debt/Eq | 3.17 | LT Debt/Eq | — |
| EPS (ttm) | -1.25 | EPS next Y | -1.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-30 | ROA | -115.28% |
| ROE | -206.10% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 744.44M |
| Shs Float | 130.36M | Short Float | 31.21% | Short Ratio | 12.11 |
| Short Interest | — | 52W High | 36.91 | 52W Low | 13.83 |
| Beta | -1.43 | Avg Volume | 2.64M | Volume | 1.50M |
| Target Price | $31.88 | Recom | Buy | Prev Close | $16.12 |
| Price | $15.68 | Change | -2.73% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$31.90
Mean price target
2. Current target
$15.68
Latest analyst target
3. DCF / Fair value
$2.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.68
Low
$12.06
High
$42.20
Mean
$31.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-02-02 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-30 | reit | Citizens | Market Outperform → Market Outperform | $40 |
| 2025-12-17 | up | Barclays | Underweight → Equal-Weight | $18 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-10-22 | reit | Guggenheim | Buy → Buy | $40 |
| 2025-10-21 | main | Barclays | Underweight → Underweight | $16 |
| 2025-10-21 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-20 | main | Citigroup | Buy → Buy | $40 |
| 2025-10-20 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-09-17 | init | Barclays | — → Underweight | $13 |
| 2025-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-08 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-09-04 | init | Guggenheim | — → Buy | $40 |
| 2025-09-03 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-08-27 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-08-19 | reit | JMP Securities | Market Outperform → Market Outperform | $40 |
| 2025-08-19 | init | Piper Sandler | — → Neutral | $21 |
- How Summit’s Deeper 2025 Loss and Ivonescimab’s FDA Path At Summit Therapeutics (SMMT) Has Changed Its Investment Story - simplywall.st Wed, 25 Feb 2026 19
- Summit Therapeutics posts $1.08B loss, FDA accepts lung cancer BLA - Stock Titan Mon, 23 Feb 2026 21
- SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Yahoo Finance ue, 24 Feb 2026 16
- SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | - GuruFocus ue, 24 Feb 2026 18
- H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty - Investing.com Nigeria Wed, 25 Feb 2026 17
- $SMMT stock is down 5% today. Here's what we see in our data. - Quiver Quantitative Fri, 23 Jan 2026 08
- SMMT: Net loss surged to $1.08B as ivonescimab advanced in Phase III and FDA review, with major new funding - TradingView Mon, 23 Feb 2026 21
- Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks Mon, 23 Feb 2026 21
- Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf Registration - Has The Bull Case Changed? - Yahoo Finance ue, 24 Feb 2026 10
- 20 new Summit hires get 10-year options on 257K shares - Stock Titan Fri, 30 Jan 2026 08
- Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus ue, 24 Feb 2026 11
- Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st ue, 24 Feb 2026 13
- Summit Therapeutics (NASDAQ: SMMT) posts 2025 loss but ends year with $713M cash - Stock Titan Mon, 23 Feb 2026 21
- Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance Fri, 30 Jan 2026 08
- Summit sets Feb. 23 webcast to review Q4 and full-year 2025 results - Stock Titan ue, 17 Feb 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14247597 | 266999968 | — | Stock Award(Grant) at price 18.74 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | D/I |
| 1 | 14247597 | 266999968 | — | Stock Award(Grant) at price 18.74 per share. | ZANGANEH MAHKAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | I |
| 2 | 53361 | 999985 | — | Stock Award(Grant) at price 18.74 per share. | SONI MANMEET SINGH | Chief Operating Officer | — | 2025-10-21 00:00:00 | D |
| 3 | 26680 | 499983 | — | Stock Award(Grant) at price 18.74 per share. | ANAND BHASKAR | Officer | — | 2025-10-21 00:00:00 | D |
| 4 | 26680 | 499983 | — | Purchase at price 18.74 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | I |
| 5 | 26680 | 499983 | — | Purchase at price 18.74 per share. | ZANGANEH MAHKAM | Chief Executive Officer | — | 2025-10-21 00:00:00 | I |
| 6 | 533617 | 9999983 | — | Purchase at price 18.74 per share. | XIA YU | Director | — | 2025-10-21 00:00:00 | I |
| 7 | 338394 | 5984756 | — | Purchase at price 17.68 - 18.07 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-09-11 00:00:00 | D |
| 8 | 338394 | 5984756 | — | Purchase at price 17.68 - 18.07 per share. | ZANGANEH MAHKAM | Chief Executive Officer | — | 2025-09-11 00:00:00 | I |
| 9 | 74545 | 196799 | — | Conversion of Exercise of derivative security at price 2.64 per share. | DUGGAN ROBERT WILLIAM | Chief Executive Officer | — | 2025-05-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -197.41M | -78.42M | -60.54M | -83.77M |
| TotalUnusualItems | -15.10M | -519.88M | -12.58M | -2.13M |
| TotalUnusualItemsExcludingGoodwill | -15.10M | -519.88M | -12.58M | -2.13M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -221.31M | -614.93M | -78.78M | -88.60M |
| ReconciledDepreciation | 89.00K | 198.00K | 1.26M | 2.46M |
| EBITDA | -212.51M | -598.30M | -73.12M | -85.91M |
| EBIT | -212.60M | -598.50M | -74.38M | -88.36M |
| NetInterestIncome | 4.78M | -6.06M | -2.89M | -242.00K |
| InterestExpense | 8.69M | 16.46M | 4.40M | 242.00K |
| InterestIncome | 13.47M | 10.40M | 1.51M | 0.00 |
| NormalizedIncome | -206.21M | -95.05M | -66.20M | -86.47M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -221.31M | -614.93M | -78.78M | -88.60M |
| TotalExpenses | 210.96M | 88.77M | 64.33M | 87.98M |
| TotalOperatingIncomeAsReported | -226.00M | -609.65M | -72.09M | -86.19M |
| DilutedAverageShares | 718.54M | 619.65M | 193.34M | 92.29M |
| BasicAverageShares | 718.54M | 619.65M | 193.34M | 92.29M |
| DilutedEPS | -0.31 | -0.99 | -0.41 | -0.96 |
| BasicEPS | -0.31 | -0.99 | -0.41 | -0.96 |
| DilutedNIAvailtoComStockholders | -221.31M | -614.93M | -78.78M | -88.60M |
| NetIncomeCommonStockholders | -221.31M | -614.93M | -78.78M | -88.60M |
| NetIncome | -221.31M | -614.93M | -78.78M | -88.60M |
| NetIncomeIncludingNoncontrollingInterests | -221.29M | -614.96M | -78.78M | -88.60M |
| NetIncomeContinuousOperations | -221.29M | -614.96M | -78.78M | -88.60M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -221.29M | -614.96M | -78.78M | -88.60M |
| OtherIncomeExpense | -15.10M | -520.13M | -12.27M | -2.17M |
| OtherNonOperatingIncomeExpenses | -252.00K | 304.00K | -39.00K | |
| SpecialIncomeCharges | -15.01M | -520.91M | -8.47M | 0.00 |
| OtherSpecialCharges | 15.01M | 520.91M | ||
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 8.47M | 0.00 |
| GainOnSaleOfSecurity | -97.00K | 1.03M | -4.11M | -2.13M |
| NetNonOperatingInterestIncomeExpense | 4.78M | -6.06M | -2.89M | -242.00K |
| InterestExpenseNonOperating | 8.69M | 16.46M | 4.40M | 242.00K |
| InterestIncomeNonOperating | 13.47M | 10.40M | 1.51M | 0.00 |
| OperatingIncome | -210.96M | -88.77M | -63.62M | -86.17M |
| OperatingExpense | 210.96M | 88.77M | 64.33M | 87.98M |
| OtherOperatingExpenses | -55.00K | -9.89M | -5.76M | |
| OtherTaxes | -313.00K | -946.00K | -4.52M | -15.21M |
| ResearchAndDevelopment | 150.78M | 59.47M | 52.00M | 85.35M |
| SellingGeneralAndAdministration | 60.50M | 30.30M | 26.74M | 23.60M |
| GeneralAndAdministrativeExpense | 60.50M | 30.30M | 26.74M | 23.60M |
| OtherGandA | 10.80M | 10.50M | 26.74M | 7.00M |
| SalariesAndWages | 49.70M | 19.80M | 19.10M | 16.60M |
| TotalRevenue | 0.00 | 0.00 | 705.00K | 1.81M |
| OperatingRevenue | 0.00 | 0.00 | 705.00K | 1.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 737.63M | 701.66M | 211.09M | 98.04M |
| ShareIssued | 737.63M | 701.66M | 211.09M | 98.04M |
| NetDebt | 28.57M | 165.70M | ||
| TotalDebt | 7.22M | 106.10M | 518.76M | 2.78M |
| TangibleBookValue | 386.88M | 75.80M | 124.86M | 70.88M |
| InvestedCapital | 388.75M | 177.69M | 640.96M | 83.28M |
| WorkingCapital | 382.02M | 169.31M | 617.93M | 71.69M |
| NetTangibleAssets | 386.88M | 75.80M | 124.86M | 70.88M |
| CapitalLeaseObligations | 7.22M | 6.10M | 4.45M | 2.78M |
| CommonStockEquity | 388.75M | 77.69M | 126.65M | 83.28M |
| TotalCapitalization | 388.75M | 177.69M | 621.19M | 83.28M |
| TotalEquityGrossMinorityInterest | 388.75M | 77.69M | 126.65M | 83.28M |
| StockholdersEquity | 388.75M | 77.69M | 126.65M | 83.28M |
| GainsLossesNotAffectingRetainedEarnings | -2.29M | -2.45M | -1.89M | -2.20M |
| OtherEquityAdjustments | -2.29M | -2.45M | -1.89M | -2.20M |
| RetainedEarnings | -1.21B | -993.26M | -378.33M | -299.55M |
| AdditionalPaidInCapital | 1.60B | 1.07B | 504.77M | 384.05M |
| CapitalStock | 7.38M | 7.02M | 2.11M | 980.00K |
| CommonStock | 7.38M | 7.02M | 2.11M | 980.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 46.81M | 125.26M | 537.51M | 30.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.08M | 104.85M | 498.73M | 4.47M |
| OtherNonCurrentLiabilities | 1.63M | 1.56M | 1.43M | 2.78M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 3.45M | 103.29M | 497.30M | 1.69M |
| LongTermCapitalLeaseObligation | 3.45M | 3.29M | 2.76M | 1.69M |
| LongTermDebt | 100.00M | 494.54M | ||
| CurrentLiabilities | 41.73M | 20.41M | 38.78M | 25.62M |
| OtherCurrentLiabilities | 1.80M | 717.00K | 662.00K | 897.00K |
| CurrentDeferredLiabilities | 0.00 | 7.94M | ||
| CurrentDeferredRevenue | 0.00 | 7.94M | ||
| CurrentDebtAndCapitalLeaseObligation | 3.77M | 2.81M | 21.46M | 1.09M |
| CurrentCapitalLeaseObligation | 3.77M | 2.81M | 1.69M | 1.09M |
| CurrentDebt | 19.77M | |||
| CurrentNotesPayable | 0.00 | 19.77M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.98M | 5.43M | 5.64M | 4.12M |
| PayablesAndAccruedExpenses | 24.19M | 11.45M | 11.02M | 11.57M |
| CurrentAccruedExpenses | 19.55M | 8.78M | 10.66M | 7.20M |
| Payables | 4.64M | 2.67M | 355.00K | 4.37M |
| AccountsPayable | 4.64M | 2.67M | 355.00K | 4.37M |
| TotalAssets | 435.56M | 202.95M | 664.17M | 113.37M |
| TotalNonCurrentAssets | 11.81M | 13.24M | 7.46M | 16.06M |
| OtherNonCurrentAssets | 1.85M | 4.32M | 577.00K | 170.00K |
| NonCurrentAccountsReceivable | 698.00K | 959.00K | ||
| GoodwillAndOtherIntangibleAssets | 1.86M | 1.89M | 1.80M | 12.41M |
| OtherIntangibleAssets | 10.40M | |||
| Goodwill | 1.86M | 1.89M | 1.80M | 2.01M |
| NetPPE | 7.40M | 6.06M | 5.08M | 3.48M |
| AccumulatedDepreciation | -1.12M | -1.04M | -1.30M | -1.04M |
| GrossPPE | 8.52M | 7.11M | 6.38M | 4.52M |
| Leases | 323.00K | 328.00K | 809.00K | 365.00K |
| OtherProperties | 7.17M | 5.88M | 4.68M | 3.34M |
| MachineryFurnitureEquipment | 1.03M | 896.00K | 889.00K | 819.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 423.75M | 189.71M | 656.71M | 97.31M |
| OtherCurrentAssets | 10.52M | 2.62M | 486.00K | 1.20M |
| RestrictedCash | 325.00K | 0.00 | 300.00M | 0.00 |
| PrepaidAssets | 2.44M | 1.50M | 7.16M | |
| Receivables | 557.00K | 848.00K | 6.12M | 24.32M |
| OtherReceivables | 1.50M | 7.16M | ||
| TaxesReceivable | 557.00K | 848.00K | 5.77M | 15.70M |
| AccountsReceivable | 0.00 | 349.00K | 1.46M | |
| CashCashEquivalentsAndShortTermInvestments | 412.35M | 186.24M | 348.61M | 71.79M |
| OtherShortTermInvestments | 307.49M | 114.82M | 0.00 | |
| CashAndCashEquivalents | 104.86M | 71.42M | 348.61M | 71.79M |
| CashEquivalents | 88.60M | 60.36M | 286.51M | |
| CashFinancial | 16.26M | 11.07M | 62.09M | 71.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -142.25M | -76.89M | -42.21M | -72.89M |
| RepaymentOfDebt | -100.00M | -24.69M | -25.00M | -110.00M |
| IssuanceOfDebt | 0.00 | 0.00 | 545.00M | 110.00M |
| IssuanceOfCapitalStock | 477.89M | 109.69M | 100.00M | 75.00M |
| CapitalExpenditure | -139.00K | -128.00K | -624.00K | -306.00K |
| InterestPaidSupplementalData | 8.81M | 10.65M | 434.00K | 85.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 52.00K | 0.00 | 7.00K |
| EndCashPosition | 105.19M | 71.42M | 648.61M | 71.79M |
| BeginningCashPosition | 71.42M | 648.61M | 71.79M | 66.42M |
| EffectOfExchangeRateChanges | -18.00K | 839.00K | -1.22M | 351.00K |
| ChangesInCash | 33.78M | -578.02M | 578.04M | 5.02M |
| FinancingCashFlow | 381.23M | 86.51M | 620.24M | 77.92M |
| CashFlowFromContinuingFinancingActivities | 381.23M | 86.51M | 620.24M | 77.92M |
| NetOtherFinancingCharges | -619.00K | -155.00K | -172.00K | |
| ProceedsFromStockOptionExercised | 3.33M | 2.13M | 399.00K | 3.09M |
| NetCommonStockIssuance | 477.89M | 109.69M | 100.00M | 75.00M |
| CommonStockIssuance | 477.89M | 109.69M | 100.00M | 75.00M |
| NetIssuancePaymentsOfDebt | -100.00M | -24.69M | 520.00M | 0.00 |
| NetLongTermDebtIssuance | -100.00M | -24.69M | 520.00M | 0.00 |
| LongTermDebtPayments | -100.00M | -24.69M | -25.00M | -110.00M |
| LongTermDebtIssuance | 0.00 | 0.00 | 545.00M | 110.00M |
| InvestingCashFlow | -205.34M | -587.77M | -624.00K | -306.00K |
| CashFlowFromContinuingInvestingActivities | -205.34M | -587.77M | -624.00K | -306.00K |
| NetOtherInvestingChanges | -15.01M | -475.01M | ||
| NetInvestmentPurchaseAndSale | -190.19M | -112.86M | 0.00 | |
| SaleOfInvestment | 489.84M | 208.16M | 0.00 | |
| PurchaseOfInvestment | -680.03M | -321.02M | 0.00 | |
| NetPPEPurchaseAndSale | -139.00K | 98.00K | -624.00K | -306.00K |
| SaleOfPPE | 0.00 | 226.00K | 0.00 | |
| PurchaseOfPPE | -139.00K | -128.00K | -624.00K | -306.00K |
| OperatingCashFlow | -142.11M | -76.76M | -41.58M | -72.59M |
| CashFlowFromContinuingOperatingActivities | -142.11M | -76.76M | -41.58M | -72.59M |
| ChangeInWorkingCapital | 15.48M | -516.00K | 9.87M | -67.00K |
| ChangeInOtherWorkingCapital | -167.00K | -359.00K | -7.13M | -813.00K |
| ChangeInOtherCurrentLiabilities | 95.00K | 0.00 | 0.00 | -1.07M |
| ChangeInOtherCurrentAssets | 2.47M | -3.42M | 215.00K | 104.00K |
| ChangeInPayablesAndAccruedExpense | 20.45M | -349.00K | 2.26M | 6.52M |
| ChangeInAccruedExpense | 18.44M | -2.61M | 6.39M | 8.23M |
| ChangeInPayable | 2.02M | 2.26M | -4.13M | -1.71M |
| ChangeInAccountPayable | 2.02M | 2.26M | -4.13M | -1.71M |
| ChangeInPrepaidAssets | -7.91M | -914.00K | 5.11M | 2.35M |
| ChangeInReceivables | 535.00K | 4.53M | 9.41M | -7.15M |
| ChangesInAccountReceivables | 0.00 | 359.00K | 975.00K | -1.14M |
| OtherNonCashItems | 15.01M | 527.17M | 3.04M | 497.00K |
| StockBasedCompensation | 50.98M | 14.11M | 11.95M | 12.80M |
| AssetImpairmentCharge | 0.00 | 474.00K | 8.47M | 0.00 |
| AmortizationOfSecurities | -2.58M | -1.92M | 0.00 | |
| DepreciationAmortizationDepletion | 89.00K | 198.00K | 1.26M | 2.46M |
| DepreciationAndAmortization | 89.00K | 198.00K | 1.26M | 2.46M |
| AmortizationCashFlow | 0.00 | 0.00 | 914.00K | 1.02M |
| AmortizationOfIntangibles | 0.00 | 0.00 | 914.00K | 1.02M |
| Depreciation | 89.00K | 198.00K | 349.00K | 1.44M |
| OperatingGainsLosses | 229.00K | -1.34M | 2.62M | 326.00K |
| NetForeignCurrencyExchangeGainLoss | 229.00K | -1.23M | 2.62M | 326.00K |
| GainLossOnSaleOfPPE | -109.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -221.31M | -614.93M | -78.78M | -88.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SMMT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|